On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

  • So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space
  • The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders
  • Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida 
  • The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company that has remained focused on developing clinical-stage compounds for diseases with high unmet medical needs. Whereas its focus is on achieving this end through accelerated regulatory pathways, the company also understands the value of innovation, forging the right partnerships, and having exemplary leadership.

So far, in 2021, Tryp has made some significant strides from an innovation standpoint, ultimately positioning itself as a first-mover in the psychedelics space.  Its lead drug candidate, TRP-8802, has proven to be promising in treating fibromyalgia (https://ibn.fm/c0oqI). The company believes that psilocybin, a critical component in its drug formulations, can be used more effective in unmet medical needs beyond mental health, and continues to explore that.

Tryp has also just announced having completed psychotherapy training and plans to initiate the upcoming phase 2a clinical trial. This trial will utilize synthetic psilocybin in combination with psychotherapy for the treatment of specific overeating disorders. The company announced that the study will be conducted at the University of Florida (“UF”) and will aim at determining the safety and efficacy of psilocybin on hyperphagia (https://ibn.fm/M3hw1). It is a tremendous milestone for Tryp and an indication of its commitment to innovate and find solutions to medical conditions that have not had tangible and reliable treatments.

Tryp has not shied away from collaborating and partnering with other players within the industry. In August, Tryp announced its partnership with Calvert Labs and Gad Consulting Services in a move that would facilitate the trial design and execution of the phase 2b clinical trials (https://ibn.fm/cHWZo). Tryp also announced the appointment of Dr. Dan Clauw to its Scientific Advisory Board on the heels of a collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School for the Fibromyalgia phase 2a clinical trial earlier in the year, a critical move for the company.

The initiation of clinical trials is an integral step within Tryp’s strategic initiatives in it’s commitment to utilizing the FDA’s 505(b)(2) regulatory pathway, and available third-party preclinical data to shorten the approval timelines and lower the overall cost of development programs (https://ibn.fm/hYjOP).

Experienced drug development leadership is also a fundamental aspect of Tryp’s operations. The company’s Chief Executive Officer (“CEO”), Mr. Greg McKee, has continued to successfully Tryp as a pioneer in the psychedelics space. In 2021 alone, the company has brought Mr. McKee onto the management team and made strategic board and advisory appointments, bringing key individuals such as Robin Carhart-Harris and Dennis Langer to help steer the company towards achieving its overall goal (https://ibn.fm/5o0DL). 

So far, Tryp has managed to have an executive and advisory team that has decades of experience working in leadership positions within critical organizations in the pharmaceutical space, such as Myriad Genetics, Syntex, Dow Chemical, Jubilant, Unigene Laboratories, and Genzyme (https://ibn.fm/7CpGI). Together, these leaders help push Tryp’s agenda and offer solutions to issues with high unmet medical needs.

2021 has been an excellent year for Tryp, as the company has made incredible strides to further its mission. It is a testament to what can be achieved once a company has the right leadership, forges the right partnerships, and continues to innovate with its products and services.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
[email protected]

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered